The FDA’s approval of the first Ebola vaccine (Ervebo) in December 2019 culminated a five-year emergency development program following West Africa’s devastating 2014-2016 outbreak.
The Crisis
The 2014 West African Ebola epidemic killed 11,325 people across Guinea, Liberia, and Sierra Leone. No approved treatments or vaccines existed. The outbreak exposed global health system failures and spurred unprecedented collaboration between WHO, pharmaceutical companies, and affected nations.
Rapid Development
Merck’s rVSV-ZEBOV vaccine (brand name Ervebo) fast-tracked through development using “ring vaccination” - immunizing contacts of infected patients and their contacts. The 2015 Guinea trial showed 100% efficacy among immediately vaccinated participants.
Approval and Deployment
WHO prequalified Ervebo in November 2019, followed by FDA approval December 19, 2019. The vaccine played a crucial role in containing the 2018-2020 Democratic Republic of Congo outbreak, which killed 2,280 despite far greater case numbers than West Africa - testament to the vaccine’s effectiveness.
Long-term Impact
Ervebo requires ultra-cold storage (-80°C to -60°C), limiting deployment in low-resource settings. A second vaccine (Johnson & Johnson’s two-dose regimen) approved in 2020 offers more practical storage. Together, they transformed Ebola from unstoppable death sentence to containable threat - if vaccines reach outbreak zones quickly.
Source: FDA Ervebo Approval